Erasca Inc (ERAS) Stock Price, Quote & News

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of E...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 465 6511

Website: www.erasca.com

Address:

3115 Merryfield Row, Suite 300, San Diego, United States

zzzdoc01 Jul. 28 at 10:17 PM

$ERAS $RVMD $VSTM is this the $VSTM thread?

0 · Reply

Alt_Fuel Jul. 28 at 8:27 PM

$VSTM $ERAS $RVMD All three VERASTEM TARGET-D registration-directed Phase 2 clinical trials now enrolling following first-patient dosing across pancreatic, colorectal, and lung cancers July 28, 2026 at 4:01 PM EDT Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-doses-first-patient-target-d-203-phase-2 TARGET-D 203 trial to evaluate VS-7375 both as monotherapy & in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort in TARGET-D 203 will also evaluate the combination of VS-7375 with cetuximab & chemotherapy for frontline treatment of metastatic colorectal cancer KRAS G12D is one of the most common KRAS variants in metastatic colorectal cancer, occurring in approximately 15% of patients

0 · Reply

Quantumup Jul. 23 at 2:37 PM

Wedbush⬆️ $RVMD to $192.10 from $181 and reiterated at Outperform after RVMD announced FDA acceptance of daraxonrasib for review in previously treated metastatic PDAC. $IMRX $ERAS TNGX BBOT ANL VSTM Wedbush said that while a PDUFA date was not disclosed, they continue to believe that a decision could come before the end of the year based on RVMD's Commissioner’s National Priority Voucher (CNPV), setting up for a late-26 to early-27 launch.

0 · Reply

Alt_Fuel Jul. 21 at 9:22 AM

$VSTM $ERAS $RVMD GenFleet Therapeutics (HKEX: 02595) announced a placement of 13.6 million new H-shares at HK$34.69 each, representing a 9.71% discount to the closing price of HK$38.42 on July 14. The deal raised HK$467 million in net proceeds, with 75% allocated to its RAS inhibitor therapies. One month chart ...

0 · Reply

Alt_Fuel Jul. 20 at 8:03 AM

$VSTM $ERAS $RVMD Early Results Of Verastem's VS-7375 In Pancreatic Cancer, Or How To Read A Reduction In CA19-9 Verastem reported >50% reduction of CA19-9 in 13 of 14 pretreated pancreatic cancer patients treated with 900 mg VS-7375. Whether CA19-9 can predict survival is another question. Chaotropy Jul 19, 2026 In April I simulated four non-covalent KRAS G12D inhibitors, and my computational model suggested Verastem’s investigational oral KRAS G12D (ON/OFF) inhibitor VS-7375 may reach the deepest signaling suppression of the group, if the published picomolar binding holds up. https://chaotropy.substack.com/p/early-results-of-verastems-vs-7375

1 · Reply

Alt_Fuel Jul. 16 at 11:41 AM

$VSTM $ERAS $IMRX $RVMD GenFleet Therapeutics announced multiple study data from its RAS-focused pipeline selected for an oral presentation or accepted for full submission of Late-breaking Abstract (LBA), at major international academic conferences in the second half of the year. The updated data of GFH375 for KRAS G12D-mutant non-small cell lung cancer (NSCLC) will be presented in an oral presentation at the IASLC 2026 World Conference on Lung Cancer (WCLC); the event will take place from September 12 to 15 in Seoul, with accepted abstracts to be released on the official WCLC website by late August. Additionally, the 2026 European Society for Medical Oncology (ESMO) Congress will be held on October 23 to 27 in Madrid. The preliminary data of another two studies from GenFleet's pipeline have been accepted for full submission of LBA, including one study evaluating GFH375 combined with cetuximab and the other investigating GFH276 monotherapy in solid tumor patients. http://www.genfleet.com/en/press_release-116

2 · Reply

biolover Jul. 15 at 7:04 PM

$ERAS the bounce was predicted based on outstanding data and $RVMD MC . They will push it to $10 B MC next days to weeks. Prior to any leak or updated data

0 · Reply

Alt_Fuel Jul. 15 at 6:27 PM

$VSTM $ANL $ERAS $IMRX $RVMD August 28, 2023 Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-enters-discovery-and-development-collaboration

0 · Reply

topstockalerts Jul. 15 at 4:49 PM

$ERAS that bounce had a lot more behind it than I gave it credit for.

1 · Reply

biolover Jul. 15 at 3:35 PM

$ERAS $RVMD $TNGX Tango was momentum last few months. Eras was as well and continues to be .. I guess they exchange roles as top moment biotch RVMD did well but my sense we peaked. But humans nature , greedy.

1 · Reply

Kaplan Fox Notifies Erasca, Inc. (ERAS) Investors of an Upcoming Lead Plaintiff Deadline on August 10, 2026

Jul 30, 2026, 10:07 AM EDT - 4 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS

Jul 27, 2026, 3:45 PM EDT - 7 days ago

Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026

Jul 27, 2026, 2:49 PM EDT - 7 days ago

ERAS Stock Drop: If You Incurred Significant Losses in Erasca, Inc., Contact Robbins LLP for Information About Recovering Your Losses

Jul 24, 2026, 9:45 AM EDT - 10 days ago

Kaplan Fox Reminds Erasca, Inc. (ERAS) Investors Seeking Recovery of the Lead Plaintiff Deadline on August 10, 2026

2026-07-20T12:00:19.000Z - 14 days ago

Erasca price target raised to $21 from $12 at Morgan Stanley

Jul 15, 2026, 4:01 PM EDT - 19 days ago

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-07-14T20:00:14.000Z - 20 days ago

Erasca price target raised to $24 from $21 at Jefferies

2026-07-14T14:05:32.000Z - 20 days ago

Erasca 31.429M share Spot Secondary priced at $17.50

2026-07-14T12:20:48.000Z - 20 days ago

Erasca price target raised to $18 from $16 at BofA

Jul 13, 2026, 11:10 PM EDT - 21 days ago

Erasca Announces Pricing of Upsized Public Offering of Common Stock

2026-07-13T20:35:11.000Z - 21 days ago

Erasca $500M Spot Secondary being re-offered at $17.50

2026-07-13T20:25:18.000Z - 21 days ago

Erasca announces $500M common stock offering

2026-07-13T20:20:09.000Z - 21 days ago

Erasca files automatic mixed securities shelf

Jul 13, 2026, 4:19 PM EDT - 21 days ago

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

2026-07-13T20:10:54.000Z - 21 days ago

Erasca announces updated preliminary ERAS-0015 data

Jul 13, 2026, 4:01 PM EDT - 21 days ago

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

2026-07-13T09:30:11.000Z - 22 days ago

Erasca initiated with Early Stage Biotech at Goldman Sachs

Jul 3, 2026, 8:00 PM EDT - 4 weeks ago

ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role

Jul 2, 2026, 5:47 PM EDT - 4 weeks ago

ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Jul 2, 2026, 8:20 AM EDT - 4 weeks ago

Robinhood and 4 More Stocks That Were Just Added to This Firm's ‘Top Picks' List

HOOD EHC EYPT MU ORCL

Jun 24, 2026, 9:24 AM EDT - 5 weeks ago

ERASCA, INC. (ERAS) INVESTOR ALERT Investors With Large Losses in Erasca, Inc. Should Contact Bernstein Liebhard LLP to Discuss Their Rights

Jun 4, 2026, 3:30 PM EDT - 2 months ago

Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset

2026-06-04T09:20:58.000Z - 2 months ago

Erasca upgraded to Neutral from Underperform at BofA

Jun 3, 2026, 3:10 PM EDT - 2 months ago

Erasca Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 8:00 AM EDT - 2 months ago

Erasca to Present at the Jefferies Global Healthcare Conference

May 13, 2026, 6:00 PM EDT - 2 months ago

Erasca Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T12:45:19.000Z - 2 months ago

Erasca price target lowered to $26 from $28 at Mizuho

2026-05-11T21:15:29.000Z - 3 months ago

Erasca reports Q1 EPS (60c), consensus (23c)

May 11, 2026, 4:01 PM EDT - 3 months ago

Erasca Reports First Quarter 2026 Business Updates and Financial Results

May 11, 2026, 4:00 PM EDT - 3 months ago

Erasca Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Erasca Quarterly report: Q1 2026

2026-05-11T17:32:53.000Z - 3 months ago

Erasca enters AURORAS-1 clinical trial pact, supply agreement with Merck

MRK

May 11, 2026, 7:00 AM EDT - 3 months ago

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

May 6, 2026, 8:00 AM EDT - 3 months ago

Erasca to Present at the Bank of America Securities Health Care Conference

2026-05-04T11:30:55.000Z - 3 months ago

Erasca recent share selloff overdone, says JPMorgan

Apr 30, 2026, 7:00 AM EDT - 3 months ago

Erasca Slides: Corporate presentation

2026-04-28T17:35:57.000Z - 3 months ago

H.C. Wainwright sees pressure for Erasca shares pending safety visibility

Apr 28, 2026, 12:29 PM EDT - 3 months ago

Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off.

2026-04-28T16:00:20.000Z - 3 months ago

Erasca falls -52.6%

Apr 28, 2026, 10:22 AM EDT - 3 months ago

Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Erasca Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Erasca Proxy statement: Proxy filing

Apr 28, 2026, 6:13 AM EDT - 3 months ago

Erasca shares sink after patient death in early-stage cancer drug trial

Apr 27, 2026, 4:30 PM EDT - 3 months ago

Erasca Transcript: Study result

Apr 27, 2026, 4:30 PM EDT - 3 months ago

Erasca Press release: Study result

Apr 27, 2026, 4:30 PM EDT - 3 months ago

Erasca Slides: Study result

Apr 27, 2026, 4:01 PM EDT - 3 months ago

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Apr 27, 2026, 8:30 AM EDT - 3 months ago

Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

Mar 12, 2026, 4:01 PM EDT - 5 months ago

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Erasca Slides: Corporate presentation

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Erasca Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Erasca Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Mar 5, 2026, 7:01 AM EST - 5 months ago

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Feb 26, 2026, 11:20 AM EST - 5 months ago

Erasca Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 24, 2026, 8:00 AM EST - 5 months ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

Feb 12, 2026, 1:00 PM EST - 6 months ago

Erasca Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 6 months ago

Erasca to Present at Upcoming Conferences in February

Jan 20, 2026, 4:01 PM EST - 6 months ago

Erasca Announces Proposed Public Offering of $150 Million of Common Stock

Jan 13, 2026, 4:30 PM EST - 7 months ago

Erasca Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 7 months ago

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Jan 10, 2026, 7:00 AM EST - 7 months ago

Erasca Slides: Corporate presentation

Jan 6, 2026, 8:00 AM EST - 7 months ago

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

zzzdoc01 Jul. 28 at 10:17 PM

$ERAS $RVMD $VSTM is this the $VSTM thread?

0 · Reply

Alt_Fuel Jul. 28 at 8:27 PM

0 · Reply

Quantumup Jul. 23 at 2:37 PM

0 · Reply

Alt_Fuel Jul. 21 at 9:22 AM

0 · Reply

Alt_Fuel Jul. 20 at 8:03 AM

1 · Reply

Alt_Fuel Jul. 16 at 11:41 AM

2 · Reply

biolover Jul. 15 at 7:04 PM

$ERAS the bounce was predicted based on outstanding data and $RVMD MC . They will push it to $10 B MC next days to weeks. Prior to any leak or updated data

0 · Reply

Alt_Fuel Jul. 15 at 6:27 PM

0 · Reply

topstockalerts Jul. 15 at 4:49 PM

$ERAS that bounce had a lot more behind it than I gave it credit for.

1 · Reply

biolover Jul. 15 at 3:35 PM

1 · Reply

Quantumup Jul. 15 at 12:16 PM

JPMorgan🏁 $TNGX and said -- We initiate coverage on TNGX with an OW rating and a Dec-2026 price target of $46. $RVMD IMRX $ERAS BBOT ANL VSTM Here's what else JPMorgan had to say: https://x.com/Quantumup1/status/2077366359768354980?s=20

0 · Reply

Alt_Fuel Jul. 15 at 10:12 AM

$VSTM ANL $ERAS $IMRX $RVMD GenFleet Therapeutics - Hong Kong Daily chart - July 15, 2026

1 · Reply

prismmarketview Jul. 14 at 8:08 PM

We are adding @Erasca (NASDAQ: $ERAS ) to the PRISM Emerging Biotech Index. Erasca is a clinical-stage precision oncology company built around the RAS/MAPK pathway, one of the most common and historically hardest-to-drug targets in cancer. Its lead program, ERAS-0015, is an oral pan-RAS molecular glue in Phase 1 for RAS-mutant solid tumors. The company reported updated Phase 1 data this week and outlined registration-enabling trials in lung and pancreatic cancer, with the next data expected in 1H27. It ended 1Q26 with $408.5M in cash and has since added $550M, funding development into 2H28. #oncology #BioTech https://prismmarketview.com/companies/erasca-inc/

0 · Reply

Alt_Fuel Jul. 14 at 7:30 PM

$VSTM Flashback ... June 26, 2026 Well, see the slide from their corporate deck. $ERAS They only have pan-Ras and pan-Kras early stage indications. They were sued by RVMD for patent violations for those too. They don't have any mutation-specific program whereas RVMD has more advanced pipeline plus multiple pipeline candidates for mutation-specific program. So, yes, they need VSTM as much as VSTM need a pan-Ras. Otherwise, their bloated MC will go down quickly. Good luck and happy Friday. https://stocktwits.com/Always_neutral/message/657642755

0 · Reply

DonCorleone77 Jul. 14 at 1:08 AM

$MBX $QTTB $PENG $USEA $ERAS AFTER-HOURS MOVERS: Currently Higher: - Lulu's Fashion Lounge (LVLU) up 29.7% after announcing review of strategic alternatives - Vision Marine Technologies (VMAR) up 14.2% after Q3 pre-announcement - Trex Company (TREX) up 5.4% after above-consensus revenue pre-announcement - Weatherford (WFRD) up 1.1% on considered re-domestication from Ireland to Delaware Currently Lower After Earnings: - FB Financial (FBK) down 1.6% Currently Also Lower: - MBX Biosciences (MBX) down 6.5% after announcing leadership transition - Q32 Bio (QTTB) down 6.8% after announcing $200M common stock offering - Penguin Solutions (PENG) down 6.9% after announcing a convertible note offering - United Maritime (USEA) down 3.8% after equity offering - Erasca (ERAS) down 1.7% after equity offering.

0 · Reply

JFais Jul. 13 at 9:49 PM

$ERAS - doubled from late April gap down, now raising $500M to put a floor in the stock + fund phase 3 in 1L PDAC & RASm NSCLC Today's update= N of 7, includes unconfirmed responses (key tell will be level of demand for the offering & whether upsized, looking at 10% dilution)

0 · Reply

biolover Jul. 13 at 9:12 PM

$ERAS small sample but RR in PDAC for ERAS 0015 is 57%. Vs < 30% for $RVMD Also 16 mg dose cleared DLT in combo with EGFR on colon ca ( daraxonrasib could not be combined due to rash ) Minimum eras molecule as good as RVMD. Very likely eras 0015 is a better molecule clinically as seen preclinically.

2 · Reply

BadBoyTrading Jul. 13 at 9:00 PM

$ERAS Erasca Announces Proposed Public Offering of $500 Million of Common Stock 📉

0 · Reply

DonCorleone77 Jul. 13 at 8:26 PM

$ERAS Erasca announces $500M common stock offering Erasca announced that it intends to offer and sell, subject to market and other conditions, $500M of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. Erasca intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the proposed offering.

0 · Reply

DonCorleone77 Jul. 13 at 8:25 PM

$ERAS Erasca announces updated preliminary ERAS-0015 data Erasca announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. The company also announced clinical development plans for the ERAS-0015 program, including potentially registration-enabling trials in lung and pancreatic cancers. There was 57% unconfirmed overall respone rate at recommended dose for expansion of 32 mg twice daily. Across doses, all patients with either confirmed or unconfirmed responses remained on treatment. At recommended dose for expansion of 32 mg once daily, 6 of 7 enrolled patients remained on treatment; at recommended dose for expansion of 24 mg once daily, 6 of 8 enrolled patients remained on treatment. Frequency and severity of treatment-related adverse events remained consistent with the company's April 2026 announcement. Mostly low-grade treatment-related adverse events, no dose-limiting toxicities, low rate of dose interruptions or reductions due to treatment-related adverse events, and no discontinuations due to treatment-related adverse events/median relative dose intensity was 100% at both 24 mg one daily and 32 mg once daily. No dose-limiting toxicities were observed for the combination in the 16 mg cohort during dose escalation in four DLT-evaluable patients. Backfill enrollment is ongoing in the 16 mg combination cohort. Dose escalation is ongoing with continued enrollment in the 24 mg combination cohort.

0 · Reply

Quantumup Jul. 13 at 7:18 PM

Goldman Sachs🏁 $ERAS with a Early-Stage Biotech rating. $RVMD $IMRX TNGX BBOT ANL Goldman Sachs said in its🏁: We initiate coverage of Erasca (ERAS) as an Early-Stage Biotech. ERAS is a clinical-stage precision oncology company developing assets in the pan-RAS and pan-KRAS space, which collectively target up to ~1/3 of all cancers, including significant portions of pancreatic (PDAC), lung (NSCLC), and colorectal cancers (CRC), representing ~130K patients/year in the U.S.. ERAS-0015 is an oral pan-RAS molecular glue (in-licensed May 2024 from Joyo Pharmatech), with preclinical and early clinical data suggestive of potential differentiation from lead competitor RVMD's daraxonrasib, which has set the standard in a field where competitors are naturally beginning to enter given the size of the market (we view ERAS as furthest along after RVMD).

0 · Reply

Alt_Fuel Jul. 10 at 5:21 PM

$VSTM $ANL $ERAS $IMRX $RVMD GenFleet Therapeutics - Hong Kong Daily chart - since IPO on September 19, 2025 ...

0 · Reply

Market Cap	5.64B
Revenue (ttm)	0.00
Net Income (ttm)	-124.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,751,800
Avg Vol	5,327,294
Day's Range	N/A - N/A
Shares Out	310.99M
Stochastic %K	26%
Beta	0.66
Analysts	Strong Sell
Price Target	$22.40